SCHEMBL14849129

SCHEMBL14849129

CN1CCN(Cc2ccc(-c3cc4nccc(Oc5ccc(NC(=O)NC6CN(C(=O)c7ccccc7)C6)cc5F)c4s3)nc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MST1R Q04912 16/20 0.59
MET P08581 4/20 0.58
KDR P35968 4/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14839978 0.93 MST1R (0.62) MST1RMETKDR
SCHEMBL14849131 0.93 MST1R (0.59) MST1RMETKDR
SCHEMBL14849168 0.92 MST1R (0.62) MST1RMETKDR
SCHEMBL14839977 0.92 MST1R (0.66) MST1RMETKDR
SCHEMBL2537128 0.90 MST1R (0.65) MST1RMETKDR
SCHEMBL14851260 0.89 MST1R (0.59) MST1RMETKDR
SCHEMBL14849170 0.88 MST1R (0.61) MST1RMETKDR
SCHEMBL2534196 0.88 MST1R (0.62) MST1RMETKDR
SCHEMBL12251147 0.86 MST1R (0.59) MST1RMETKDR
SCHEMBL2533404 0.86 MST1R (0.59) MST1RMETKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130090327-A1 Inhibitors of Protein Tyrosine Kinase Activity METHYLGENE INC. (CA) 2013-04-11 US disclosed
US-20130090327-A1 Inhibitors of Protein Tyrosine Kinase Activity METHYLGENE INC. (CA) 2013-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090327-A1 Inhibitors of Protein Tyrosine Kinase Activity KDR, FLT1, FLT4 MST1R 42/4885MET 25/4885KDR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.